Bone Biologics Corporation (BBLGW) Operating cash flow 2016–2025
Bone Biologics Corporation (BBLGW) annual operating cash flow history from SEC filings — net cash provided by operating activities each fiscal year.
-$2.7MFY2025 · since FY2016: -$7.3M → -$2.7M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$2.7M | +34.8% |
| FY2024 | -$4.1M | +56.8% |
| FY2023 | -$9.6M | -167.9% |
| FY2022 | -$3.6M | -190.3% |
| FY2021 | -$1.2M | -187.8% |
| FY2020 | -$426,933 | +86.9% |
| FY2019 | -$3.3M | +20.8% |
| FY2018 | -$4.1M | -23.3% |
| FY2017 | -$3.3M | +54.6% |
| FY2016 | -$7.3M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More BBLGW financial trends
BBLGW RevenueBBLGW Net incomeBBLGW Net marginBBLGW Gross profitBBLGW Gross marginBBLGW Operating incomeBBLGW Operating marginBBLGW Free cash flowBBLGW Capital expendituresBBLGW Return on equityBBLGW Stock buybacksBBLGW Dividends paidBBLGW Total assetsBBLGW Total liabilitiesBBLGW Shareholders’ equityBBLGW overview →